NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: VILINBIO · data 2026-11-01
Vilin Bio Med Ltd.
In plain words
Price: 14.6% below its 52-week high of ₹60.95.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹42 cr |
| Net profit (last 12 months) | ₹2 cr |
| Sales growth, 3 years (yearly) | 50.8% |
| Profit growth, 3 years (yearly) | 15.7% |
At a glance
P/E 40.9, P/B 2.8, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 7.5%, ROCE 11.3%, operating margin 6.9%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 15.7% and sales growth 50.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Profit grew 15.7% a year over 3 years.
- Low return on equity (7.5%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Vilin Bio Med Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Vilin Bio Med Ltd.'s P/E ratio?
About 40.9, based on the last 12 months' earnings and a price of ₹52.05 (data 2026-11-01).
What is the 52-week high and low of Vilin Bio Med Ltd.?
The 52-week high is ₹60.95 and the 52-week low is ₹18.95.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Vilin Bio Med Ltd. | ₹52.05 | ₹73 cr | 40.9 | 2.8 | 7.5% | 11.3% | 0.01 | +106.5% |
| Vaishali Pharma Ltd. | ₹6.42 | ₹87 cr | 19.6 | — | 6.2% | 3.6% | 0.27 | -37.1% |
| Sunil Healthcare Ltd. | ₹61.55 | ₹70 cr | 17.7 | — | 5.9% | 6% | 0.8 | -13.3% |
| Onyx Biotec Ltd. | ₹36 | ₹65 cr | — | — | -0.4% | 0.5% | 0.27 | -12.4% |
| Zenith Drugs Ltd. | ₹37 | ₹63 cr | 16.1 | 0.9 | 5.5% | 9.3% | 0.75 | -40.5% |
| Vivimed Labs Limited | ₹5.53 | ₹51 cr | — | — | — | -43.6% | — | +5.3% |
Compare VILINBIO with VAISHALI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VILINBIO in NSE Scanner →